Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
Who: Pfizer/Voyager Therapeutics
What: Pfizer is licensing adeno-associated virus (AAV) delivery technology from Voyager for its gene therapy efforts
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
